Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01303835 · ClinicalTrials.gov registry record · Phase 2
Low Dose Naltrexone for Glioma Patients
A Phase 2 study, sponsored by Katy Peters.
- Completed
- Registry status
- Phase 2
- Development phase
- 110
- Enrollment target
NCT01303835 is a Phase 2 study that has completed, run by Katy Peters. The registered enrollment target is 110 participants.
The verdict
NCT01303835, a Phase 2 study, has completed, sponsored by Katy Peters.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 110 participants
- Enrollment target
Study Summary
To compare the effects of low dose naltrexone (LDN) versus placebo on quality of life in high grade glioma patients undergoing standard chemoradiation
Interventions
- DRUG Placebo
- DRUG LDN
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2011-05 |
| Est. Completion | 2015-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01303835
The ClinicalTrials.gov registry entry for NCT01303835 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Katy Peters, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01303835 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01303835 about?
NCT01303835 is a clinical study titled "Low Dose Naltrexone for Glioma Patients". To compare the effects of low dose naltrexone (LDN) versus placebo on quality of life in high grade glioma patients undergoing standard chemoradiation
What is the current status of trial NCT01303835?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 110 participants. The study started on 2011-05. Estimated completion is 2015-05.
What interventions are being tested in trial NCT01303835?
The interventions under investigation include: Placebo (DRUG), LDN (DRUG).
Who is sponsoring clinical trial NCT01303835?
This trial is sponsored by Katy Peters, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.